



Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call

October 17, 2013

PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 17, 2013-- [Pacira Pharmaceuticals, Inc.](http://www.pacira.com) (NASDAQ:PCRX) today announced that financial results for the company's third quarter ended September 30, 2013, will be released before the market opens on Thursday, October 31, 2013. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Thursday, October 31, 2013, at 9 a.m. ET. The call can be accessed by dialing 1-866-318-8618 (domestic) or 1-617-399-5137 (international) five minutes prior to the start of the call and providing the passcode 26728091.

A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), and providing the passcode 62860661. The replay of the call will be available for two weeks from the date of the live call.

The live, listen-only webcast of the conference call can be accessed by visiting the "Investors & Media" section of the company's website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.

About Pacira

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the United States in April 2012. EXPAREL and two other products have utilized the Pacira proprietary product delivery technology DepoFoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.

Source: Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc.
Investor Contact:
Jessica Cho, 973-254-3574
Investor Relations Associate